KALA BIO (KALA) “celebrated the landmark Executive Order” signed by U.S. President Donald Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA:
- Kala Bio Delays 2025 Annual Report Filing
- Red Light Holland engages Kala Bio with its Researgency.ai platform
- Morning News Wrap-Up 3/11/26: Wednesday’s Biggest Stock Market Stories!
- KALA BIO Stock Rockets on Plans to Become the ‘Palantir for Biotech’
- Kala Bio poised to ship first commercial AI product in about 14 days